Ipilimumab/pembrolizumabInflammatory polyarthritis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1735卷 / 1期

关键词：

D O I：

10.1007/s40278-019-56779-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：163 / 163

相关论文

共 50 条

[1] Ipilimumab/pembrolizumabInflammatory myositis: case report
Reactions Weekly, 2019, 1753 (1) : 205 - 205
[2] Ipilimumab/nivolumab/pembrolizumabInflammatory arthritis: 6 case report
Reactions Weekly, 2018, 1692 (1) : 192 - 192
[3] Ipilimumab/nivolumabDiarrhea, seronegative polyarthritis and panuveitis: case report
Reactions Weekly, 2022, 1916 (1) : 238 - 238
[4] PembrolizumabInflammatory arthritis: case report
Reactions Weekly, 2021, 1837 (1) : 571 - 571
[5] PembrolizumabInflammatory myopathy: case report
Reactions Weekly, 2018, 1693 (1) : 408 - 408
[6] PembrolizumabInflammatory arthropathy: case report
Reactions Weekly, 2017, 1681 (1) : 284 - 284
[7] PembrolizumabInflammatory orbitopathy: case report
Reactions Weekly, 2019, 1751 (1) : 313 - 313
[8] PembrolizumabInflammatory arthritis: case report
Reactions Weekly, 2019, 1734 (1) : 404 - 404
[9] PembrolizumabInflammatory CNS lesion: case report
Reactions Weekly, 2016, 1601 (1) : 191 - 191
[10] Ipilimumab/nivolumab/pembrolizumabInflammatory arthritis and various other toxicities: 9 case reports
Reactions Weekly, 2020, 1804 (1) : 163 - 163

← 1 2 3 4 5 →